Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBIT (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBIT for 12 consecutive years, with -$64.7 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 6.8% to -$64.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$256.0 million through Dec 2025, up 25.61% year-over-year, with the annual reading at -$256.0 million for FY2025, 25.61% up from the prior year.
  • EBIT for Q4 2025 was -$64.7 million at ImmunityBio, down from -$55.6 million in the prior quarter.
  • The five-year high for EBIT was -$55.6 million in Q3 2025, with the low at -$111.6 million in Q1 2023.
  • Average EBIT over 5 years is -$82.2 million, with a median of -$82.6 million recorded in 2022.
  • The sharpest move saw EBIT plummeted 156.67% in 2021, then skyrocketed 32.32% in 2025.
  • Over 5 years, EBIT stood at -$79.3 million in 2021, then dropped by 7.1% to -$84.9 million in 2022, then dropped by 0.58% to -$85.4 million in 2023, then increased by 18.72% to -$69.4 million in 2024, then rose by 6.8% to -$64.7 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$64.7 million, -$55.6 million, and -$71.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.